Skip to contentV
Vaccinex, Inc.
V
VCNXVaccinex, Inc. Q2 2023 · 10-Q
Revenue$0.00$0.00derivedno prior Q2 2022 on file Net Income-$7.06M-$7.06MN/M vs Q2 2022 EPS Diluted-$24.54-$24.54N/M vs Q2 2022 Operating Income-$7,077,000N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Vaccinex, Inc. · CIK 1205922 · Engraved from SEC EDGAR
Operating Cash Flowderived-$5,507,000N/M Free Cash Flowderived-$5,507,000— ended Jun 30, 2023 · filed Aug 14, 2023 · 45 d after period end